CL2020002766A1 - Formulaciones farmacéuticas mejoradas - Google Patents

Formulaciones farmacéuticas mejoradas

Info

Publication number
CL2020002766A1
CL2020002766A1 CL2020002766A CL2020002766A CL2020002766A1 CL 2020002766 A1 CL2020002766 A1 CL 2020002766A1 CL 2020002766 A CL2020002766 A CL 2020002766A CL 2020002766 A CL2020002766 A CL 2020002766A CL 2020002766 A1 CL2020002766 A1 CL 2020002766A1
Authority
CL
Chile
Prior art keywords
pharmaceutical formulations
formulation
improved pharmaceutical
combination
sorbitol
Prior art date
Application number
CL2020002766A
Other languages
English (en)
Inventor
Ganeshchandra Sonavane
Parag Lokhande
Pradeep Sethi
Tushar Wagh
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66290450&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020002766(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of CL2020002766A1 publication Critical patent/CL2020002766A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona una formulación farmacéutica sólida fluida que comprende uno o más principios activos y una combinación que comprende sorbitol y parafina líquida, un envase que contiene la formulación, un procedimiento para la fabricación de la formulación y el uso de la combinación en la formulación.
CL2020002766A 2018-05-02 2020-10-26 Formulaciones farmacéuticas mejoradas CL2020002766A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201811016594 2018-05-02

Publications (1)

Publication Number Publication Date
CL2020002766A1 true CL2020002766A1 (es) 2021-02-19

Family

ID=66290450

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002766A CL2020002766A1 (es) 2018-05-02 2020-10-26 Formulaciones farmacéuticas mejoradas

Country Status (16)

Country Link
US (2) US11648201B2 (es)
EP (2) EP3787596B1 (es)
JP (1) JP7516259B2 (es)
KR (1) KR20210005224A (es)
CN (1) CN112040929B (es)
BR (1) BR112020021852A2 (es)
CA (1) CA3099055A1 (es)
CL (1) CL2020002766A1 (es)
CO (1) CO2020013679A2 (es)
ES (1) ES3041575T3 (es)
FI (1) FI3787596T3 (es)
MX (2) MX2020011541A (es)
PH (1) PH12020551798A1 (es)
PL (1) PL3787596T3 (es)
SG (1) SG11202010792TA (es)
WO (1) WO2019211159A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4146164T3 (da) * 2020-05-08 2025-05-26 Fertin Pharma As Flowpack til oral afgivelse af aktive ingredienser
TW202430129A (zh) * 2023-01-17 2024-08-01 荷蘭商菲林公司 改進的西地那非藥物配製物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2716624B1 (fr) * 1994-02-25 1996-05-03 Jouveinal Lab Gelée laxative hypocalorique à base d'huile de paraffine liquide et de lactulose, son procédé de préparation.
ITFI970184A1 (it) 1997-07-30 1999-01-30 Menarini Farma Ind Composizioni farmaceutiche contenenti vitamina d e calcio,loro preparazione ed uso terapeutico
RU2175554C2 (ru) 1999-03-30 2001-11-10 Пермское научно-производственное объединение "Биомед" Оральный препарат интерферона в виде таблеток
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
RU2216319C1 (ru) * 1999-11-30 2003-11-20 Панацея Биотек Лимитед Быстрорастворимая фармацевтическая композиция в виде твердой лекарственной формы с пролонгированным сладким вкусом и способ ее получения
WO2006020534A2 (en) * 2004-08-09 2006-02-23 Dr. Reddy's Laboratories Ltd. Stabilized desloratadine composition
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
WO2006102494A2 (en) 2005-03-23 2006-09-28 Elan Pharma International Limited Nanoparticulate corticosteroid and antihistamine formulations
US7611739B2 (en) 2006-01-06 2009-11-03 Amerilab Technologies, Inc. Method of using guava extract and composition including guava extract
US20090004270A1 (en) * 2006-01-06 2009-01-01 Amerilab Technologies, Inc. Method of using guava extract
EP1970053A1 (en) 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
CA2713112A1 (en) * 2008-02-13 2009-08-20 Ratiopharm Gmbh Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide
CN101970008B (zh) 2008-03-10 2013-10-30 拜耳消费者保健股份公司 含有抗酸剂和唾液刺激剂的可口的固体组合物
CA2719246A1 (en) * 2008-03-26 2009-10-01 Taro Pharmaceuticals North America, Inc. Stabilizing lipid compositions for oral pharmaceutical agents
TR200806298A2 (tr) 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Farmasötik formülasyon
RU2454221C2 (ru) 2010-07-06 2012-06-27 Общество с ограниченной ответственностью "Завод Медсинтез" Способ получения лиофилизированного противовирусного средства
EP2468258A1 (en) 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
CN103429223A (zh) 2011-01-17 2013-12-04 武田药品工业株式会社 口腔分散片
WO2013077829A1 (en) * 2011-11-21 2013-05-30 Mahmut Bilgic Water-soluble pharmaceutical granules
WO2013172999A1 (en) * 2012-05-16 2013-11-21 Mewa Singh Pharmaceutical compositions for the delivery of substantially water-insoluble drugs
US20160128944A1 (en) 2013-06-04 2016-05-12 Vyome Biosciences Pvt. Ltd. Coated particles and compositions comprising same

Also Published As

Publication number Publication date
US20230346704A1 (en) 2023-11-02
US20210236426A1 (en) 2021-08-05
BR112020021852A2 (pt) 2021-02-23
PL3787596T3 (pl) 2025-11-12
ES3041575T3 (en) 2025-11-13
EP4603095A3 (en) 2025-11-19
KR20210005224A (ko) 2021-01-13
EP3787596A1 (en) 2021-03-10
CN112040929B (zh) 2024-08-30
JP7516259B2 (ja) 2024-07-16
PH12020551798A1 (en) 2021-06-14
CO2020013679A2 (es) 2021-03-19
EP4603095A2 (en) 2025-08-20
TW202002953A (zh) 2020-01-16
CN112040929A (zh) 2020-12-04
MX2023008569A (es) 2023-08-08
EP3787596B1 (en) 2025-06-25
MX2020011541A (es) 2020-11-24
US12016955B2 (en) 2024-06-25
US11648201B2 (en) 2023-05-16
JP2021522299A (ja) 2021-08-30
WO2019211159A1 (en) 2019-11-07
FI3787596T3 (fi) 2025-09-29
CA3099055A1 (en) 2019-11-07
SG11202010792TA (en) 2020-11-27

Similar Documents

Publication Publication Date Title
IL279034A (en) Pharmaceutical combination, composition and formulation containing a glucokinase activator and an alpha-glucosidase inhibitor, preparation methods and uses thereof
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
SV2017005426A (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
ECSP17007538A (es) 2-(morfolin-4-il)-1,7-naftiridinas
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
CL2021000741A1 (es) Composiciones plaguicidas sinérgicas y métodos para distribución de ingredientes activos insecticidas
CL2018003418A1 (es) Formulaciones de óxido de polialquileno-asparaginasa y métodos de preparación y uso del mismo.
AR104482A1 (es) Sistema de suministro de multi cámara
UY36898A (es) Variantes de hppd y métodos de uso
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
MX2020007896A (es) Material portador para la liberacion de uno o varios agentes activos en una formulacion para el cuidado del hogar.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
MX2018005250A (es) Sistema con nebulizador y recipiente.
CL2018001590A1 (es) Composiciones farmacéuticas que comprenden algun derivado de fenilaminopirimidina.
CL2020002766A1 (es) Formulaciones farmacéuticas mejoradas
MX387472B (es) Composiciones para el cuidado bucal y sistema para dispensar las mismas.
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
MX2017007596A (es) Procedimiento para fabricar partículas de resinato de fenilefrina; partículas de resinato de fenilefrina; y uso de las partículas de resinato de fenilefrina en formulaciones farmacéuticas.
CL2018002577A1 (es) Forma física de un modulador sgr
AR107986A1 (es) Solubilización mejorada a través del uso de una combinación de surfactantes de cadena extendida
EA201990127A1 (ru) Депо-препарат
MX2016009567A (es) Composicion antifungica.
PT3986378T (pt) Composições farmacêuticas sob a forma de gel que contêm xiloglucano e álcoois para a libertação controlada de ingredientes ativos